Annual Report 10-11 - Elder Pharmaceuticals Ltd.

Recommendations

Info

Brands representour distinctiveassetsElder Pharmaceuticals has created an enormous intellectual asset base in the preceding twoWe have created brands like Shelcal, which not only acts as a calcium supplement, but alsoand is amongst the top three revenue generators of the company, which have performedElder’s R&D centre worked extensively on the development of a chewable form of co-enzymeQ10, offering optimum dosage of 100 mg per tablet - making it more palatable and acceptable16
Annual Report2010 - 11Company OverviewBoard and Management ReportsFinancial Statements28 th Shelcal has establishedBUSINESS SEGMENTS AND PRODUCT LINESWomen’s Healthcarepre-menstrual syndrome, infertility to menopause as well as problems related tovitamin necessities, labour/parturition and hormonal imbalance through dosage ofProductsMarket opportunitiesWe have already launched different variants of Shelcal to meet the growing`calcium supplementin the market, havingWound care/Pain ManagementProductsMarket opportunitiesestimated at `Chymoral isa market leader in itssegment with a robust17
Page 2 and 3: COMPANY OVERVIEWNiche is the result
Page 4 and 5: Niche is theresult of innovat vespi
Page 6: Chairman’s MessageDear Shareholde
Page 12 and 13: A niche isan intellectual space,whi
Page 14 and 15: Creatinga niche throughowned market
Page 16 and 17: Niche expertiseDEVELOPINGINTERNATIO
Page 20 and 21: Nutraceuticalscombination specializ
Page 23 and 24: 28 th Annual Report2010 - 11Company
Page 27 and 28: Annual Report2010 - 11Company Overv
Page 33 and 34: Directors’ Report28 th Annual Rep
Page 37 and 38: Annexure - I28 th Annual Report2010
Page 41 and 42: Report on CorporateGovernance28 th
Page 53 and 54: Auditors’ Report28 th Annual Repo
Page 57 and 58: for the year ended 31st March 20112
Page 59 and 60: Cash Flow Statement28 th Annual Rep
Page 61 and 62: Schedules to Balance Sheetas at 31s
Page 67 and 68: year ended 31st March 201128 th Ann
Page 69 and 70:
28 th Annual Report2010 - 11Schedul
Page 71:
28 th Annual Report2010 - 11Company
Page 74 and 75:
8. Purchases of Finished Goods :` P
Page 76 and 77:
ParticularsGratutity31st March2011
Page 78 and 79:
BALANCE SHEET ABSTRACT AND COMPANY'
Page 80 and 81:
Pharmaceuticals Ltd.Consolidated Ba
Page 82 and 83:
Pharmaceuticals Ltd.Consolidated Ca
Page 84 and 85:
Pharmaceuticals Ltd.Consolidated Sc
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Pharmaceuticals Ltd.year ended 31st
Page 92 and 93:
Pharmaceuticals Ltd.year ended 31st
Page 94 and 95:
Pharmaceuticals Ltd.Exchange differ
Page 96 and 97:
Pharmaceuticals Ltd.As At31st March
Page 98 and 99:
Pharmaceuticals Ltd.CONSOLIDATED BA
Page 100 and 101:
International FZCO, Dubai, U.A.E.Fi
Page 102 and 103:
International FZCO, Dubai, U.A.E.Fi
Page 104 and 105:
Somerta Holdings Co. Limited (Cypru
Page 106 and 107:
Pharmaceuticals Ltd.NoticeNotice is
Page 108 and 109:
Pharmaceuticals Ltd.including terms
Page 110 and 111:
Pharmaceuticals Ltd.9. The dividend
Page 112 and 113:
Pharmaceuticals Ltd.Notes..........
Page 114 and 115:
Pharmaceuticals Ltd.Notes..........
Page 116:
Pharmaceuticals Ltd.ELECTRONIC CLEA
Page 120:
Elder HouseC-9, Dalia Industrial Es
show all

Annual Report 10-11 - Elder Pharmaceuticals Ltd.

Create successful ePaper yourself

Delete template?

Save as template?